Side EffectsDrug Interaction Evidence and CYP EnzymesPart 4: TablesOncology drugs where CYP3A4 and P‑gp are important pharmacokinetic (PK) considerationsCYP3A4 and P-gp supplement–drug interactionsDrug Interaction Evidence and CYP EnzymesPrevious PageOncology drugs where CYP3A4 and P‑gp are important pharmacokinetic (PK) considerationsNext Page